NCT03648333View on ClinicalTrials.gov

Clinical Trial to Assess the Pharmacokinetic Characteristics of Lodivixx Tab. 5/160mg in Healthy Male Subjects (N=27)

PHASE1CompletedINTERVENTIONAL
Enrollment

27

Participants

Timeline

Start Date

December 31, 2013

Primary Completion Date

February 28, 2014

Study Completion Date

June 30, 2014

Conditions
Healthy Male Subjects
Interventions
DRUG

Exforge tab. 10/160mg

DRUG

Lodivixx tab. 5/160mg

All Listed Sponsors
lead

Hanlim Pharm. Co., Ltd.

INDUSTRY

NCT03648333 - Clinical Trial to Assess the Pharmacokinetic Characteristics of Lodivixx Tab. 5/160mg in Healthy Male Subjects (N=27) | Biotech Hunter | Biotech Hunter